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ABSTRACT: There is a paucity of data describing the impact
of salt counterions on the biological performance of inhaled
medicines in vivo. The aim of this study was to determine if the
coadministration of salt counterions inﬂuenced the tissue
permeability and airway smooth muscle relaxation potential of
salbutamol, formoterol, and salmeterol. The results demon-
strated that only salbutamol, when formulated with an excess
of the 1-hydroxy-2-naphthoate (1H2NA) counterion, exhibited
a superior bronchodilator eﬀect (p < 0.05) compared to
salbutamol base. The counterions aspartate, maleate, fumarate,
and 1H2NA had no eﬀect on the ability of formoterol or
salmeterol to reduce airway resistance in vivo. Studies using
guinea pig tracheal sections showed that the salbutamol:1H2-
NA combination resulted in a signiﬁcantly faster (p < 0.05) rate of tissue transport compared to salbutamol base. Furthermore,
when the relaxant activity of salbutamol was assessed in vitro using electrically stimulated, superfused preparations of guinea pig
trachea, the inhibition of contraction by salbutamol in the presence of 1H2NA was greater than with salbutamol base (a total
inhibition of 94.13%, p < 0.05). The reason for the modiﬁcation of salbutamol’s behavior upon administration with 1H2NA was
assigned to ion-pair formation, which was identiﬁed using infrared spectroscopy. Ion-pair formation is known to modify a drug’s
physicochemical properties, and the data from this study suggested that the choice of counterion in inhaled pharmaceutical salts
should be considered carefully as it has the potential to alter drug action in vivo.
KEYWORDS: salbutamol, ion-pair, airways, counterion, pharmaceutical salt, 1H2NA
1. INTRODUCTION
A pharmaceutical salt is particularly susceptible to the
composition of body ﬂuids into which it dissolves because
there is the potential that the drug can partake in a number of
diﬀerent noncovalent physical interactions. For example, if the
pharmaceutical salt dissolves into a ﬂuid that allows the drug to
ionize, ion-pairs can be formed in solution.1 Ion pairs usually
arise from the drug interacting with coadministered salt
counterions, which can in turn modify a drug’s physicochemical
behavior.2
Not every pharmaceutical salt will be susceptible to ion-pair
formation upon dissolution in body ﬂuids.3 The formation of
an ion-pair complex between the ionized drug and coadminis-
tered ionized counterion is dependent upon the physicochem-
ical properties of the drug, the physicochemical properties of
the ion-pair, the aﬃnity of the two molecules, and the route of
administration.1 For example, when a pharmaceutical salt is
administered orally, the drug is exposed to a relatively large
volume of liquid, and hence, if a labile, noncovalent bond is
formed between the drug and the counterion, it will most
probably be broken when faced by rapid dilution and
competition from charged species in the gut ﬂuids, unless the
ion-pair binding is very strong. Such a scenario has led to the
regulatory approval of several salt forms of the same drug for a
single therapeutic indication when dosed orally because the
diﬀerent salt forms appear to be bioequivalent.4 However, this
does not mean that all salts are bioequivalent. The biological
consequences of delivering therapeutic agents as pharmaceut-
ical salts via routes which do not expose the molecules to such a
large volume of ﬂuid, e.g., the skin and the airways, may be
more signiﬁcant compared to oral administration.
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Previous literature has suggested that changes in drug
transmembrane permeation as a result of ion-pair formation
has a major inﬂuence on the ability of salt counterions to
modify the parent drug’s behavior.5−7 In addition, data
generated in vitro has suggested that ion-pairs can remain
intact upon crossing biological barriers,8 and therefore it may
be possible that a parent drug’s behavior is inﬂuenced by a salt
counterion, even after absorption into the body. However,
there appears to be very limited information about the
consequence of ion-pair formation in vivo.9 This is surprising
given the number of pharmaceutical salts that are used
clinically, and it suggests that further research into the manner
of how coadministered counterions inﬂuence the biological
behavior of pharmaceutical salts is required.
The primary aim of this study was to investigate the potential
of a coadministered counterion to alter the biological behavior
of a drug, which forms a pharmaceutical salt, in vivo. The
inhaled route was chosen for this study due to the low volume
of liquid in which the drug and counterion dissolve and the fact
that the ability of an ion-pair to alter the physicochemical
properties of an inhaled drug has already been established.10
The β2- adrenoceptor (AR) agonists salbutamol, salmeterol,
and formoterol were selected as the drug molecules in this work
because they are all commercially available as pharmaceutical
salts and are widely used clinically for the treatment of asthma
and chronic obstructive pulmonary disease (COPD).11 In
addition, salbutamol has already been studied in vitro with a
number of counterions including sulfate,10,12 adipate, stearate,10
succinate,12 acetate monomethanolate,13 and hydrochloride,14
and this provided vital information upon which to base the in
vivo work. As the physical and chemical properties of the
salbutamol salts have already been characterized10,12,15 this
study initially focused on the pharmacodynamic consequences
of drug−counterion coadministration. However, to better
understand the drug−counterion mixtures that elicited changes
in pharmacodynamics responses, an attempt was made to
characterize the strength of the drug−counterion interactions,
to elucidate the eﬀects of the counterions upon tissue
permeation, and to understand the inﬂuence of the counterions
upon the drug’s pharmacological action. The counterions
aspartate, maleate, fumarate, and 1H2NA were selected to
represent a series of compounds that were used clinically,
displayed diﬀerent physicochemical properties, and because
they had the potential to form ion-pairs with the β2-AR
agonists. The drug−counterion combinations used in the study
were based upon the molecules’ compatibility in the solution
state at the concentrations that were used in the work. As it was
anticipated that the interaction aﬃnity between the drug and
counterions would be relatively weak, the therapeutic agents
were administered in all the studies with an excess of
counterions to maximize the interactions between the β2-AR
agonist and the counterions. While it was accepted that this
does not necessarily mimic the use of a pharmaceutical salt in
vivo, as they are typically presented to the body with lower
counterion concentrations, the experiments were designed in
this manner to continually present the test agents to diﬀerent in
vitro and in vivo systems in a similar state, even when the ﬂuids
used in assays varied. This was an essential experimental design
trait of this work that allowed the study data to be directly
compared across the test systems. In addition, to mimic the
inhaled administration of “pharmaceutical salts”, which typically
are produced as powders, a production method for each drug−
counterion combination would be required to produce the
lowest energy salt form in the solid state. This would be a
considerable piece of work and the reporting of the physical
data, which would be needed to support the use of these
compounds, would detract from the in vivo aspect of the study
which was our focus. Therefore, simple solutions of the drugs
and the counterions were used as the test samples in this work.
2. MATERIALS AND METHODS
2.1. Materials and Reagents. Salbutamol base (BN.
H80619) was a kind gift from Cipla Ltd., Mumbai, India.
Salbutamol sulfate (BN. B027798) was obtained from
GlaxoSmithKline Research and Development, Ware, U.K.
Salmeterol xinafoate (BN. SX-0081010) was purchased from
Vamsi Laboratories, India. Salmeterol base and formoterol base
were synthesized by Tocris Cookson Ltd., Avonmouth, Bristol,
U.K. Formoterol fumarate dihydrate (BN. 27000M0
A0031421) was obtained from Arena Pharmaceuticals,
Buckingham, U.K. Phosphate buﬀered saline (PBS) tablets
(0.15 M, pH 7.3) were purchased from Oxoid, Basingstoke,
U.K. Whatman nylon ﬁlters (pore size 0.2 μm, diameter 47
mm) were purchased from Fisher Scientiﬁc Ltd., Lough-
borough, U.K. Methanol (Fisher Scientiﬁc Ltd., U.K.) and
ammonium acetate (Sigma-Aldrich Company Ltd., Poole,
Dorset, U.K.) were of high performance liquid chromatography
(HPLC) grade. Indomethacin, sodium hydroxide, hydrochloric
acid, 1-hydroxy-2-naphthoate (1H2NA), bombesin acetate,
maleic acid, L-aspartic acid, sodium chloride, potassium
chloride, calcium chloride dihydrate, magnesium sulfate,
sodium bicarbonate, potassium dihydrogen phosphate, and D-
glucose were all purchased from Sigma-Aldrich Company Ltd.,
Poole, Dorset, U.K., and were of analytical grade.
2.2. Animals. Experiments were conducted under a project
license issued by the United Kingdom Home Oﬃce in
accordance with the United Kingdom Animal Scientiﬁc
Procedures Act, 1986. Protocols were approved by the Local
Ethical Review Committee of King’s College London. All in
vivo experiments were performed with male Dunkin-Hartley
guinea pigs (250−500 g, Charles River). Guinea pigs were
housed in animal holding facilities maintained at 18−19 °C
with a standard 12 h light−dark cycle. A maximum of six guinea
pigs were housed per cage, containing sawdust and hay with
cardboard tunnels in order to provide environmental enrich-
ment. Animals were fed ad libitum on a FD1 guinea pig diet
(Special Diets Services, Witham, Essex, U.K.) with free access
to water.
2.3. Lung Function Studies. Male Dunkin-Hartley guinea
pigs (250−500 g) were anesthetized with urethane (25% w/v, 7
mL kg−1, ip), and a neuromuscular blocker was administered to
induce skeletal muscle paralysis (succinylcholine chloride, 1 mg
kg−1, im). The trachea, carotid artery, and both jugular veins
were cannulated for measurement of airway obstruction and
systemic blood pressure and for iv administration of test
substances, respectively. An iv infusion was used to dose the
ion-pairs, as this minimized the potential of nonequivalent
doses reaching the tissue as a consequence of diﬀerences in
deposition and absorption via the inhaled route. The tracheal
cannula was attached to a pneumotachograph that was in turn
connected to a pressure transducer (±2 cm H2O, model MP-
45-14-871, Validyne Engineering). Changes in airﬂow were
measured using a lung function recording system (version 9.2;
Mumed Systems, London, U.K.) and were displayed in real
time on a personal computer. The ﬂow signal was integrated to
give a measure of tidal volume. A cannula was inserted into the
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thoracic cavity between the third and ﬁfth ribs and connected
to the negative side of the pressure transducer (±20 cm H2O,
Validyne). The positive side of the pressure transducer was
connected to the side of the pneumotachograph proximal to
the animal to obtain a measure of transpulmonary pressure
(diﬀerence between mouth and thoracic pressure). The lung
function parameter, total airway resistance (RL; cm of water per
L per s), was derived from each measure of ﬂow, tidal volume,
and transpulmonary pressure by integration. Animals were
allowed to acclimatize for 10 min prior to the start of the study.
For bronchodilator experiments, bronchoconstriction was
induced by means of continuous iv administration of bombesin
(2−4 μg kg−1), which elicited sustained submaximal increases
in total airway resistance, as described elsewhere.16 After stable
bronchoconstriction had been obtained, salbutamol was
formulated with sulfate as it was supplied (2:1 ratio) at 0.1,
1, 10, 100, or 1000 μg kg−1, and 1H2NA at a molar ratio of
1:10. Formoterol fumarate and salmeterol xinafoate were used
as supplied at 0.1, 1, 10, or 100 μg kg−1. Formoterol base and
salmeterol base were formulated with maleate or aspartate at a
ratio of 1:10. The dose was increased when the eﬀect of the
previous dose had reached a plateau. Bronchodilation was
calculated as the percentage reversal of the increase in total lung
resistance induced by bombesin. Data were expressed as
arithmetic means ± standard error of the mean (SEM).
2.4. Salbutamol Counterion Interaction Studies. For
the analysis of salbutamol in the presence of the hydrophobic
counterion 1H2NA a UV/vis spectrophotometer (PerkinElmer
Ltd., Beaconsﬁeld, U.K.) was used. Standard stock solutions of
salbutamol base and 1H2NA were prepared in deionized water
(pH 6.5 measured using a pH meter) and adjusted using 0.1 M
sodium hydroxide and/or hydrochloric acid. Solutions of
salbutamol base and 1H2NA were mixed to achieve a
concentration range of 0.005−0.84 mM for 1H2NA and a
constant salbutamol base concentration of 0.42 mM, made up
to volume using deionized water. The ﬁnal pH of the samples
was checked and adjusted to pH 6.5. Samples were scanned
between 190 and 400 nm using a UV quartz cuvette (path
length 10 mm). A background reading of a “blank” solution was
preceded by three replicate readings of each sample. The
spectral data was converted into an Excel ﬁle for analysis.
For the infrared (IR) studies, solutions of salbutamol base
and salbutamol in the presence of sulfate were prepared in
deuterated water and deuterated methanol (80:20). Solutions
of salbutamol base and salbutamol in the presence of 1H2NA
were prepared in a 70:30 ratio of deuterated methanol to
deuterated water. All samples were adjusted to pH 6.5 using 0.1
M sodium hydroxide and/or hydrochloric acid, and checked
again at the end of the study. Spectra were obtained with the
aid of a universal Omni-Cell system (Specac Ltd., Orpington,
Kent, U.K.) for the analysis of liquids equipped with calcium
ﬂuoride (CaF2) windows (Mylar spacer at 0.025 mm path
length). A double solvent subtraction procedure was employed
for all spectra. Samples were scanned on average 32 times, with
a resolution of 4 cm−1 over the 550−4000 cm−1 range. Data
was recorded using a Spectrum One spectrometer, and spectral
analysis was performed with Spectrum version 5.3.1 software
(PerkinElmer Ltd., Beaconsﬁeld, U.K.).
2.5. Lung Tracheal Transport Studies. Transport
experiments were carried out in unjacketed, individually
calibrated, upright Franz diﬀusion cells (MedPharm Ltd.,
U.K.). Guinea pigs were killed by a blow to the head, followed
by exsanguination; the trachea was excised and placed in cold
physiological saline (0.9% sodium chloride, pH 5.5). The
adherent connective tissue was dissected away and the lumen
gently ﬂushed with saline. The trachea was dissected into rings
consisting of 5−6 cartilage bands and mounted between the
donor and receiver chambers, which were sealed together using
paraﬁlm. Small magnetic bars were inserted into each of the
receiver compartments to ensure adequate mixing. The receiver
compartments were ﬁlled with physiological saline (0.9%
sodium chloride, pH adjusted to 7.4), and each cell was
checked by inversion for leaks. The assembled Franz cells were
placed in a 37 °C water bath and allowed to equilibrate for 60
min prior to addition of 300 μL of the donor solution
(salbutamol base, salbutamol sulfate (commercial salt), or
salbutamol in the presence of 1H2NA). The salbutamol base
concentration was ﬁxed at 0.00178 M for all test systems. An
excess of 1H2NA was presented at a concentration of 17.8 ×
10−3 M to mimic the in vivo studies. All samples were made up
to volume using deionized water (pH 7.4), and the ﬁnal pH was
adjusted to 7.4 using 0.1 M sodium hydroxide or hydrochloric
acid. Samples (0.2 mL) were taken for reverse phase high
performance liquid chromatography (RPHPLC) analysis
(method I or II detailed below) at 0 (prior to addition of the
donor solution), 15, 30, 45, 60, 120, 180, 240, 300, 360, 1320,
1380, and 1440 min after the donor solution was added to the
cells. Following sampling each receiver cell compartment was
replaced with fresh prewarmed physiological saline (0.9%
sodium chloride, pH adjusted to 7.4) of equal volume. The
cumulative amount of drug (μg) transported through the
trachea per unit area (cm2) was corrected for sample removal
and plotted against time (min). Steady-state ﬂux was calculated
using the line of best ﬁt over a minimum of ﬁve time points
with a linearity of R2 ≥ 0.97 and displayed as mean ± standard
deviation (SD). Where appropriate, a two-tailed, unpaired,
Student’s t-test was used for statistical analysis with a 95%
conﬁdence interval.
2.6. Reverse Phase High Performance Liquid Chro-
matography (RPHPLC). 2.6.1. Method I. Separation of
salbutamol base and salbutamol sulfate was achieved using a
SphereClone ODS2 (250 × 4.6 mm, particle size: 5 μm)
column (Phenomenex Ltd., Cheshire, U.K.) maintained at 50
°C using a thermostated column compartment, TCC-100
(Dionex Corporation, Sunnyvale, CA, USA). The mobile phase
was a mixture of aqueous ammonium acetate solution 0.1% and
methanol (80:20) at pH 4.5, ﬁltered through a 0.2 μm nylon
membrane and degassed by sonication. The mobile phase ﬂow
rate was 1.0 mL min−1, the injection volume was 20 μL, and
detection was set at 272 nm. Quantitative determination of the
active substance was performed using a RPHPLC system
consisting of a Dionex P680 pump, a Dionex PDA-100
photodiode array detector, and a Dionex ASI-100 automated
sampler injector with Chromeleon Client version 6.60 for
analysis (Dionex Corporation, Sunnyvale, CA, USA).
2.6.2. Method II. Separation of salbutamol base and
salbutamol in the presence of 1H2NA was achieved using a
SphereClone ODS2 column, maintained at 50 °C using a
thermostated column block heater TCC-100. The mobile phase
was a mixture of aqueous ammonium acetate solution 0.1% and
methanol (80:20) at pH 6.0, ﬁltered through a 0.2 μM nylon
membrane and degassed by sonication. The stationary phase
was used with a 1.2 mL min−1 ﬂow rate and a 20 μL injection
volume. The compounds were analyzed at a wavelength of 276
nm.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.6b00448
Mol. Pharmaceutics 2016, 13, 3439−3448
3441
Both RPHPLC methods were shown to be ﬁt for purpose in
terms of precision (≤2%), accuracy (≥99%), linearity (R2 >
0.9999), and sensitivity (limit of detection < 0.53 μg mL−1;
limit of quantiﬁcation < 1.78 μg mL−1). A two-tailed, unpaired,
Student’s t-test determined no signiﬁcant (p > 0.05) diﬀerences
of the average retention times between salbutamol base assayed
alone or in the presence of counterions.
2.7. In Vitro Contractility of Isolated Guinea Pig
Trachea. Superfusion of guinea pig tracheal rings was
performed according to a previously described method.17,18
Guinea pigs were sacriﬁced by cervical dislocation, and the
tracheas were excised and cut into rings. Each tracheal ring (3−
5 cartilage bands) was opened by sectioning the ring opposite
the smooth muscle and sectioned to form strips. A cotton
thread was attached to the cartilage at one end of the strip for
attachment to the tension gauge, and a cotton loop to the other
end for anchoring the tissue to a ﬁxed stainless steel hook. The
tissue was then suspended between two platinum electrodes
under 1 g tension and superfused at a rate of 3 mL min−1
(Watson-Marlow Sci-Q 323S peristaltic pump and a 318MC
eight roller ﬁve channel micro pump head, Cornwall, U.K.)
through a jacketed, glass heat exchanger with Krebs−Henseleit
(K−H) solution (37 °C, 5% CO2, 95% O2) containing the
cyclooxygenase inhibitor indomethacin (5 μM) to inhibit the
release of endogenous prostaglandins and reduce spontaneous
tone of the airway smooth muscle.
K−H solution (pH 7.2−7.4) was composed of 118 mM
sodium chloride, 4.7 mM potassium chloride, 2.5 mM calcium
chloride dihydrate, 1.2 mM magnesium sulfate, 25 mM sodium
bicarbonate, 1.2 mM potassium dihydrogen phosphate, and
11.1 mM D-glucose made up to volume in deionized water.
The tracheal preparations were equilibrated for 40 min
before commencement of electrical ﬁeld stimulation (EFS)
delivered as 10 s trains of square wave pulses at 3 Hz, 0.1 ms
duration, and 30 V generated every 100 s by means of a
physiological square wave stimulator (Digitimer MultiStim
System-D330, Digitimer Ltd., Herts, U.K.). Changes in tension
detected by the tension gauge were recorded using a Powerlab/
8sp (AD Instruments, Castle Hill, Australia). Ten minutes after
the initiation of airway smooth muscle stimulation, the trachea
was superfused with K−H solution containing the drug of
interest by slow infusion. The drug was delivered at a rate of
0.275 mL min−1 using a syringe pump (Original-Perfusor-
Spritze, B. Braun Medical, Melsungen, Germany) to which a
butterﬂy-25G short winged infusion tube (Abbott, Sligo,
Republic of Ireland) was attached for 20 min, after which
superfusion with drug was terminated. The tissues were then
superfused with drug free K−H solution, and tension was
monitored for a further 6 h. The maximum−minimum (g) peak
height for the period of contraction was calculated oﬄine by
using LabChart 7 Reader software (AD Instruments, Hastings,
U.K.).
All EFS data are expressed as percentage inhibition of the
contractile response obtained prior to the administration of the
drug and displayed as mean ± standard error of the mean
(SEM). Onset time (OT50 and OT75) was expressed as the time
taken from administration of the drug to achieve 50% or 75%
control (predrug) value (minutes) and was determined by
interpolation from the plot of percentage against time to attain
50% or 75% inhibition of the response. Likewise, the recovery
(or oﬀset) time (RT50 and RT75) was expressed as the time
taken from stopping the administration of the drug to achieve
50% or 75% recovery of the contractile response (predrug)
value (minutes). It was determined by interpolation from a plot
of percentage response (% control) against time to attainment
of 50% or 75% recovery from that response.
Data was analyzed using a Kruskal−Wallis nonparametric
one way analysis of variance (ANOVA) with post hoc Dunn’s
multiple comparison test. The ﬁnal concentration of salbutamol
base on the tissue remained constant at 1 μM. The
hydrophobic counterion, 1H2NA, was added to salbutamol
base (1 μM) in excess of 10-fold (10 μM). Salbutamol sulfate
was at a total concentration of 1 μM. All samples were made up
to volume in deionized water and adjusted to pH 7.4 with 1 M
sodium hydroxide and/or hydrochloric acid.
2.8. Data and Statistical Analysis. All data analysis was
performed using Graphpad Prism (Prism, version 5; GraphPad
Software Inc., San Diego, CA). Data was analyzed for normality
using the Anderson−Darling test. Where appropriate, a two-
tailed, unpaired, Student’s t-test was used and statistically
analyzed at the 95% conﬁdence level. In vitro data was analyzed
using a one way ANOVA Kruskal−Wallis test with post hoc
Dunn’s multiple comparison test. In vivo data was analyzed
using a one way analysis of variance (ANOVA) with a post hoc
Tukey’s multiple comparison test or a two way ANOVA with
post hoc Bonferroni test and considered signiﬁcant at a p value
less than 0.05.
3. RESULTS
3.1. The Eﬀect of Salbutamol Base, Salbutamol
Sulfate, and Salbutamol in the Presence of 1H2NA on
Lung Function in Vivo. An iv infusion of the peptide
bombesin induced an increase in airway resistance in all animals
(Figure 1). A 100% increase in resistance was desired, and the
dose of bombesin was adjusted accordingly. Bombesin induced
airway obstruction by 85−123% in the animals.
Figure 1. Representative trace of changes in total lung resistance following iv administration of bombesin (2 μg kg−1), followed by iv administration
of salbutamol base (SAL) at regular intervals (0.1, 1, 10, 100, and 1000 μg kg−1).
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Salbutamol base (0.1, 1, 10, 100, and 1000 μg kg−1),
salbutamol sulfate (0.1, 1, 10, 100, and 1000 μg kg−1), and
salbutamol in the presence of 1H2NA (0.1:1, 1:10, and 10:100
μg kg−1) all elicited a dose-related reduction in the bombesin-
induced resistance (Figure 2). These data seem to suggest that
the bronchodilator eﬀect of the diﬀerent salbutamol products
diﬀered between the treatment groups (Figure 2, Figure S1).
Salbutamol in the presence of 1H2NA at 10 μg kg−1 reversed
peak resistance by 81.30 ± 3.59% (n = 7) (p < 0.05, two way
ANOVA with post hoc Bonferroni test vs salbutamol base),
whereas at a similar dose, salbutamol sulfate only reversed peak
resistance by 59.44 ± 6.78% (n = 5), and salbutamol base by
only 52.47 ± 11.92%.
3.2. The Eﬀect of Counterions on Lung Function upon
Administration of Formoterol and Salmeterol. Formoter-
ol base (0.1, 1, and 10 μg kg−1), formoterol fumarate (0.1, 1,
and 10 μg kg−1), formoterol in the presence of maleate, and
formoterol in the presence of aspartate (0.1:1, 1:10, and 10:100
μg kg−1) all elicited a dose-related reduction in resistance
induced by bombesin (Figure 3, Figure S2). However, the
percentage reversal of airway obstruction of the diﬀerent
formoterol products was very similar (Figure 3).
Salmeterol base appeared to have a very diﬀerent dose−
response proﬁle compared to salbutamol and formoterol; for
example, salmeterol displayed very little relaxation of the tissue
at 0.1 and 1 μg kg−1 unlike the other bronchodilators (Figure 4,
Figure S3). However, as with formoterol, the presence of
counterions did not seem to inﬂuence the performance of
salmeterol, i.e., all the dose response proﬁles were similar both
with and without the salt counterions (Figure 4). Only
salmeterol maleate showed a signiﬁcantly slower eﬀect at
reversing peak resistance compared to salmeterol xinafoate, but
only at 10 μg kg−1 (p < 0.05, two-tailed unpaired, Student’s t-
test) (Figure 4).
3.3. Salbutamol Counterion Interaction Studies. Using
Fourier transform infrared spectroscopy (FT-IR) measure-
ments the salbutamol base sample showed a peak at 1606 cm−1
in solution, which was assigned to the secondary amine (Figure
5). A signiﬁcant shift in this secondary amine bend was
observed for salbutamol base (1606 cm−1) compared to
salbutamol presented as the commercial sulfate (1617 cm−1)
(Figure S4). The N−H bend (∼1616 cm−1) of salbutamol was
also modiﬁed with increasing concentrations of sulfate (Figure
5). At 35 mM sulfate, a peak height ratio (1606 and 1617 cm−1)
change was detected. The peak height ratio continued to
change with increasing sulfate concentrations until the 1606
cm−1 peak disappeared with 158 mM sulfate. The peak height
ratio, determined using the peaks at ∼1606 cm−1 and ∼1618
cm−1, was used to calculate the percentage of salbutamol bound
to sulfate in solution, and this was plotted against the free
sulfate concentration in order to calculate a log aﬃnity constant
of 0.85 ± 0.03, assuming a 1:1 association (note: we did not
consider a 1:2 salbutamol sulfate ratio to be relevant in solution
due to the weak binding and the relatively low amount of
counterion present). In the presence of 1H2NA the spectral
splitting of the 1615 peak indicated that an ion-pair was formed.
However, these spectral changes occurred at a 10-fold lower
concentration compared to the sulfate counterion. Unlike for
the sulfate counterion the overlapping signals made it
impossible to calculate the peak ratio and construct a binding
curve (Figure 5). Attempts were made to use UV/vis
Figure 2. Bronchodilating eﬀect of salbutamol base (0.1, 1, 10, 100,
and 1000 μg kg−1, pH 7.4), salbutamol sulfate (0.1, 1, 10, 100, and
1000 μg kg−1, pH 7.4), and salbutamol in the presence of 1H2NA
(0.1:1, 1:10, and 10:100 μg kg−1, pH 7.4) on bombesin-induced
increase in total lung resistance. Points represent mean ± SEM; n =
3−7. Two way ANOVA with post hoc Bonferroni test, (*) p < 0.05 vs
salbutamol base.
Figure 3. Bronchodilator eﬀect of formoterol base (0.1, 1, and 10 μg
kg−1, pH 7.4), formoterol fumarate (0.1, 1, and 10 μg kg−1, pH 7.4),
formoterol in the presence of maleate, and formoterol in the presence
of aspartate (0.1:1, 1:10, and 10:100 μg kg−1, pH 7.4) on bombesin-
induced increases in total lung resistance. Points represent mean ±
SEM; n = 3−4.
Figure 4. Bronchodilator eﬀect of salmeterol base (0.1, 1, 10, and 100
μg kg−1, pH 7.4), salmeterol xinafoate (0.1, 1, 10, and 100 μg kg−1, pH
7.4), salmeterol in the presence of maleate, and salmeterol in the
presence of aspartate (0.1:1, 1:10, 10:100, and 100:1000 μg kg−1, pH
7.4) on bombesin-induced increase in total lung resistance. Points
represent mean ± SEM; n = 3−5. Two-tailed unpaired, Student’s t-
test. (*) p < 0.05 vs salmeterol xinafoate.
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spectroscopy to support the IR data, but the salbutamol base
lambda max at 276.43 nm did not shift (Figure S5). To
facilitate the subsequent in vitro and in vivo studies, the HYSS
microspeciation software (Protonic Software, U.K.) was used to
calculate the optimum ratio for salbutamol:counterion that
would generate ion-pairs at pH 7.4 employing the measured
aﬃnity constant for salbutamol sulfate (given that the 1H2NA
binding was ca. 10-fold stronger). These results suggested that
at a 1:10 drug to counterion molar ratio with the ion-paired
species would be formed (data not shown).
3.4. Salbutamol Transport Across Biological Mem-
branes. The ﬂux of the commercial salbutamol sulfate mixture
through the tracheal tissue was 1.17 ± 0.27 μg/cm2/min
(Figure 6). This ﬂux for salbutamol sulfate was similar to that
for salbutamol in the presence of 1H2NA (1.49 ± 0.14 μg/
cm2/min), but both systems containing the counterions
displayed a signiﬁcantly greater ﬂux than that of salbutamol
base alone at 0.34 ± 0.07 μg/cm2/min (p < 0.0001, two-tailed,
unpaired, Student’s t-test). The cumulative mass of salbutamol
base (0.00178 M) that transported into the receiver solution
was 97.30 ± 18.94 μg/cm2 at 360 min (Figure 6). The
cumulative mass of salbutamol (0.00178 M) that transported
across the guinea pig tracheal tissue when presented with an
excess of the hydrophobic counterion, 1H2NA (0.0178 M), at
360 min was 335.08 ± 28.16 μg/cm2, and this was signiﬁcantly
greater (p < 0.0001, two-tailed, unpaired, Student’s t-test) than
that of salbutamol base alone (Figure 6). The lag time to
steady-state ﬂux of salbutamol in the presence of 1H2NA was
signiﬁcantly higher than that of the base (138.91 ± 8.27 min
with 1H2NA vs 87.60 ± 5.54 min for the base; p < 0.0001, two-
tailed, unpaired, Student’s t-test), whereas the lag time for
salbutamol sulfate crossing the lung tracheal tissue was lower
than that for the base at 28.97 ± 6.52 min (p < 0.0001, two-
tailed, unpaired, Student’s t-test). The apparent permeability
(Papp (cm/s)) of salbutamol base in the presence of 1H2NA
and in the presence of sulfate was also signiﬁcantly greater than
that of the base alone (p < 0.0001, two-tailed, unpaired,
Student’s t-test) (Table 1).
3.5. The Inhibitory Actions of Salbutamol, Salbutamol
Sulfate, and Salbutamol in the Presence of 1H2NA on
EFS-Induced Contractions of Isolated Guinea Pig
Tracheal Smooth Muscle. The superfusion of salbutamol
base (1 μM) in deionized water (pH 7.4) caused an 84.24 ±
0.64% inhibition of the tissues with an OT50 of 5.00 ± 0.00 min
and an OT75 of 8.75 ± 1.03 min. Both the OT50 and OT75 for
salbutamol sulfate were signiﬁcantly faster compared to
salbutamol base alone (p < 0.01 and p < 0.05 respectively,
one way ANOVA Kruskal−Wallis test with post hoc Dunn’s
multiple comparison test) (Table 2). However, the total
percentage inhibition of the tissue superfused with salbutamol
sulfate was similar to that of the base (p > 0.05, one way
ANOVA Kruskal−Wallis test with post hoc Dunn’s multiple
comparison test). The tissue recovery indices of the base and
sulfate forms of salbutamol were also similar (p > 0.05, one way
ANOVA Kruskal−Wallis test with post hoc Dunn’s multiple
comparison test). All of the tissues recovered to 100% of the
predrug value, and the tissues that had been treated with
salbutamol were not signiﬁcantly diﬀerent (p > 0.05, one way
ANOVA Kruskal−Wallis test with post hoc Dunn’s multiple
comparison test) compared to the drug free controls (Table 2).
Figure 5. FT-IR spectra of (A) salbutamol base in the presence of increasing sulfate and (B) salbutamol base in the presence of increasing 1H2NA
concentrations in the liquid state (80% deuterated water and 20% deuterated methanol, pH 6.5). The number denotes the concentration (mM) of
counterion present against a ﬁxed salbutamol base concentration (42 mM).
Figure 6. Transport of salbutamol base (0.00178 M, pH 7.4),
salbutamol sulfate (0.00178 M:0.00037 M, pH 7.4), and salbutamol in
the presence of excess 1H2NA (0.00178:0.0178 M, pH 7.4) across
guinea pig lung tracheal tissue into saline (pH 7.4). Each point
represents the mean cumulative mass per area ± SD (n = 5−12). Two-
tailed, unpaired, Student’s t-test, (***) p < 0.0001 vs salbutamol base.
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Salbutamol (1 μM) in the presence of excess 1H2NA (10
μM) had an OT50 similar to that of salbutamol base (p > 0.05,
one way ANOVA Kruskal−Wallis test with post hoc Dunn’s
multiple comparison test). However, the OT75 for salbutamol
in the presence of 1H2NA was signiﬁcantly faster with an onset
time of 4.38 ± 0.89 min compared to 8.75 ± 1.03 min for the
base (p < 0.05, one way ANOVA Kruskal−Wallis test with post
hoc Dunn’s multiple comparison test). The inhibition of
contraction by salbutamol in the presence of 1H2NA was also
greater than that by salbutamol base alone, with a total
inhibition of 94.13% (p < 0.05, one way ANOVA Kruskal−
Wallis test with post hoc Dunn’s multiple comparison test).
The time for the tissues to reach 50% recovery compared to the
predrug values, for both salbutamol base and salbutamol in the
presence of 1H2NA, was approximately 50 min (p > 0.05, one
way ANOVA Kruskal−Wallis test with post hoc Dunn’s
multiple comparison test). However, the average time taken
for the tissues to recover to 75% of the predrug value for
salbutamol in the presence of 1H2NA was faster (p < 0.01, one
way ANOVA Kruskal−Wallis test with post hoc Dunn’s
multiple comparison test). All of the tissues recovered to
100% of the predrug value and were not signiﬁcantly diﬀerent
from both controls (p > 0.05, one way ANOVA Kruskal−Wallis
test with post hoc Dunn’s multiple comparison test) (Table 2).
4. DISCUSSION
Of the diﬀerent drug−counterion combinations assessed only
the salbutamol 1H2NA ion-pair had an eﬀect on airway smooth
muscle relaxation (ASM) when compared with salbutamol base.
It could be argued that the enhanced smooth muscle relaxation
of salbutamol in the presence of 1H2NA could have been a
consequence of this molecule having an independent action on
ASM as it was presented to the tissue in a molar excess
compared to salbutamol base. There is little information in the
literature regarding the eﬀect of 1H2NA on biological tissues,
but Groeben and Emala19 did evaluate the eﬀect of xinafoic acid
(1H2NA) on ASM, in particular its ability to bind to the β2-AR.
In this previous work it was concluded that 1H2NA had no
direct airway irritant eﬀects, had no direct bronchodilating
eﬀects in vivo, and it was thought that it did not interfere with
β2-AR binding in vitro, nor impair the binding of salmeterol to
β2-AR. The data from the present study, which showed an
eﬀect of 1H2NA with salbutamol, but not with salmeterol,
concurred with the previous suggestions that the 1H2NA
eﬀects were not dependent on any direct interaction with β2-
receptors.
The ability of drug−ion pair formation to enhance drug
absorption has been reported in the literature.1,6,20 In addition,
it has already been established in previously published work
that a number of anionic drugs can form complexes with
1H2NA. However, there seems to be an absence of studies that
determine the ion-pair association using direct spectroscopy
and then go on to understand their pharmacological eﬀects.
This is presumably because the ionic and other noncovalent
interactions (i.e., hydrogen bonding) that occur between the
ionic drug and the counterion during ion-pair formation are
relatively weak,21,22 and in aqueous solvents the water signals
make the detection of any spectral shifts diﬃcult to
observe.23,24 Despite these issues, in the present study, we
attempted to generate direct spectroscopy evidence of ion-pair
formation, but as a simple aqueous solution was not capable of
dissolving salbutamol and the test counterions, methanol was
added to aid solubility. It was known that the presence of
methanol would inﬂuence the absolute values for the aﬃnity
constant compared to a pure water system, but it was believed
that by keeping a constant solvent system across the
measurements it would not detract from the comparative
measurements made in the current study. In addition, there are
methods available to predict aﬃnity constants in water from
experimental data with water−methanol solvents.25
The FT-IR spectroscopy data generated in this study
substantiated that salbutamol formed an ion-pair with sulfate
and 1H2NA. However, a full binding curve could only be
obtained for the salbutamol sulfate salt. The spectral shifts for
Table 1. Flux (μg/cm2/min) and Apparent Permeability (Papp) of Salbutamol Base, Salbutamol Sulfate, and Salbutamol in the
Presence of Excess 1H2NA, through Guinea Pig Tracheal Tissue into Saline pH 7.4 at 37 °Ca
drug detection (min) slope vs time (min) ﬂux (μg/cm2/min) R2 Papp (cm/s) n
salbutamol base 60 120−360 0.34 ± 0.07 0.9992 1.31 ± 0.28 × 10−5 5
salbutamol sulfate (commercial) 30 60−360 1.17 ± 0.27 0.9717 4.57 ± 1.08 × 10−5 12
salbutamol 1H2NA 180 180−360 1.49 ± 0.14 0.9964 5.84 ± 0.57 × 10−5 5
aThe concentration of salbutamol remained constant at 0.00178 M. Each value of the ﬂux represents the mean ± standard deviation.
Table 2. Percentage Control (%) of Tissues after Drug Addition, and Percentage Tissue Recovery at 360 min Post Dosing,
Onset Time (OT50, OT75) To Achieve 50% or 75% Control (Predrug) Value and Recovery Time (RT50, RT75) to Return to 50%
or 75% of Control (Predrug) Value (min) for Salbutamol Base (SAL, 1 μM), Salbutamol Sulfate (SAL Sulfate, 1 μM), and
Salbutamol in the Presence of 1H2NA (1 μM:10 μM) at pH 7.4 in Isolated Guinea Pig Tracheaa
test substance
control water SAL SAL sulfate SAL + 1H2NA
OT50 (min) 5.00 ± 0.00 2.51 ± 0.00** 4.37 ± 0.62
OT75 (min) 8.75 ± 1.03 3.89 ± 0.97* 4.38 ± 0.84*
control (%) 108.19 ± 5.90 106.04 ± 4.97 15.79 ± 0.64 17.98 ± 2.33 5.87 ± 1.96**
RT50 (min) 53.34 ± 2.64 53.34 ± 0.00 51.25 ± 2.08
RT75 (min) 84.17 ± 2.50 74.17 ± 0.00 61.67 ± 0.00**
control (360 min; %) 108.19 ± 3.74 104.88 ± 4.89 101.97 ± 2.13 99.07 ± 2.11 102.64 ± 2.98
N 5 3 5 3 4
aResults expressed as mean ± SEM. A one way ANOVA Kruskal−Wallis test with post hoc Dunn’s multiple comparison test was used for statistical
comparison: (*) p < 0.05 vs salbutamol base; (**) p < 0.01 vs salbutamol base.
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1H2NA occurred at a 10-fold lower concentration compared to
salbutamol, and despite not being able to generate an absolute
value for the binding aﬃnity between salbutamol and 1H2NA,
the data allowed us to predict with some conﬁdence that the
salbutamol−1H2NA ion-pair would be formed at the 1:10 ratio
of drug:counterion that was used across all the experiments.26
For salbutamol, which is thought to enter the tissue primarily
via the paracellular route,27 the formation of the ion-pairs could
have modiﬁed tissue uptake by making the transcellular route
more favorable since the formation of a complex would have to
some extent reduced the charge and hydrophilicity of the
salbutamol molecule.1 The comparative eﬀects of this counter-
ion enhanced drug transport process would be much less for
formoterol and salmeterol because it is thought that these
molecules are naturally transported by the transcellular route,
even without the addition of a counterion, due to their greater
hydrophobicity.28 It has been hypothesized that once deposited
into the airways formoterol moves eﬃciently across the airway
epithelium and into the lamina propria, where it diﬀuses toward
ASM by partitioning into the lipid bilayer and then
progressively leaches out to interact with the β2-AR active
site.29 Salmeterol contains a longer side chain than the shorter
acting β2-agonist salbutamol that makes it >10000 times more
lipophilic, and so it has also been hypothesized to move readily
through the epithelial cell membrane.30
Although superfusion studies were not completed in this
work for salmeterol or formoterol, previous studies have shown
that both formoterol and salbutamol display a faster onset time
compared to salmeterol.31,32 Furthermore, formoterol is known
to be more potent than salmeterol in both in vitro and in vivo
studies.31,32 This information from the literature compliments
the lung function studies in the current work where formoterol
seemed to have a greater degree of inhibition compared to
salmeterol alone and in the presence of counterions across the
concentration range (0.1−10 μg kg−1).33 This suggested that
the in vivo systems used in this study were working well. The
lack of a signiﬁcant diﬀerence observed when the counterions
were combined with formoterol (Figure 3) or salmeterol
(Figure 4) may be due to the choice of counterions. The ability
to form an ion-pair that will remain complexed for long enough
to inﬂuence its pharmacological behavior is related to the
chemical structure and physicochemical properties of the
parent drug and the counterions present. The curve for
salmeterol in the presence of the maleate counter ion was
signiﬁcantly diﬀerent from that for salmeterol xinafoate, and the
dose response proﬁles for salmeterol base and salmeterol
aspartate were very diﬀerent from that of salmetrol xinafoate
(Figure 4). These small diﬀerences could be exploited by
investigating alternative counterions which may have a strong
aﬃnity for the parent drug.
As the 1H2NA counterion has been previously shown to
form ion-pairs with a wide range of drug molecules,1 it was
thought that it would be worthwhile to further understand the
transport of salbutamol 1H2NA into lung tissue using an in
vitro model. As the inﬂuence of ion-pairs on a range of cell lines
has previously been established in vitro,1,34 in this work we
wanted to use ex vivo tissue such that we could understand not
only passage through the epithelial barrier, but also drug
permeation across through pulmonary tissue as this has
relevance to both locally administered and systemically
administered agents. Although we accept that only a limited
amount of drug is absorbed through the tracheal tissue, this
section of the respiratory tract provided signiﬁcant rigidity to
allow drug transport to be assessed. A 60 min equilibration time
was needed to ensure that the Franz cells were secure, free of
bubbles, and at a temperature of 37 °C.35,36 As these conditions
remained constant throughout the work, it was unlikely that the
application of the liquid, which can change apical ion channel
abundance, and hence cause increased ﬂuxes due to activation
of ﬂuid homeostasis mechanisms, had an eﬀect on the data set
trends.37
For the in vitro lung trachea transport studies the hypothesis
was that ion-pair formation enhanced the ability of salbutamol
to move into the tissue. Salbutamol base at pH 7.4 is very
hydrophilic with a cLogD7.4 of −1.32 (MarvinSketch,
ChenAxon Ltd.), and it is fully ionized (calculated amine pKa
= 9.02 ± 0.028) from pH 8 and below; therefore there is not a
pH dependent change in the transport of salbutamol across the
physiological pH range.38 Although lung lining ﬂuid is slightly
acidic (pH 6.9),39 the transport studies were conducted at pH
7.4 to prevent a pH gradient across the cells as this could
inﬂuence transport. Furthermore, a pH of 7.4 is typically used
in cell culture models when characterizing salbutamol trans-
port.40 These physicochemical properties enable fast dissolu-
tion of the parent drug to occur when it is administered as a
solid, but salbutamol’s polarity results in only a moderate
aﬃnity with the cellular epithelium of tracheal tissue. Evidence
for the transcellular route being the main path of entry into the
pulmonary tissue has been generated through transport
inhibition studies using other charged molecules such as
amino acids.27 More recent studies have also suggested the
involvement of organic cation transporters (OCTs) in tissue
accumulation and cellular uptake of inhaled drugs.41,42 As
salbutamol base carries a net positive charge at physiological
lung pH,43 OCTs may be involved in the absorption and
clearance processes for this drug in the lung without the
formation of an ion-pair,42,43 but the OCT’s capacity to take up
a neutral ion-pair would presumably be diminished.
The association of 1H2NA with salbutamol would generate a
larger, more neutral molecule, which would be inherently more
hydrophobic than the parent.34,44 It is these changes in
physicochemical properties that would most likely drive the
increase in aﬃnity of the ion-pair for the lung tissue compared
to the parent drug.45,46 The increase in transport lag time,
which traditionally occurs as a consequence of an increase in
molecular size of a compound,47 and the higher Papp of
salbutamol in the presence of 1H2NA support this hypothesis.
The Papp values reported in the literature for salbutamol range
by 2 orders of magnitude from 1.5 × 10−8 (porcine tissue)48 to
5.2 × 10−6 cm/s (Calu-3 cells).49 The salbutamol base Papp of
1.31 ± 0.28 × 10−5 cm/s reported in the current work was
approximately double the highest of these previously reported
values, and this was considered to be due to the diﬀerent
permeability of guinea pig trachea. No previous work has used
this tissue to test drug transport, and our transport data
suggested that the barrier was conﬂuent.
The sulfate counterion could also have a similar eﬀect to
1H2NA on salbutamol transport, but the charging on the
sulfate at pH 7.4 would mean that a neutral complex is unlikely
to be formed and the transport of the salbutamol sulfate may be
a little more complex than the 1H2N salbutamol ion pair.
However, it was noteworthy that the sulfate counterion
displayed the ability to alter the transport into the tissue,
even at the 1:2 drug:counterion ratio. The cLogD7.4 of 1H2NA
is predicted to be −0.53 (MarvinSketch software (ChemAx-
on)), making it a more lipophilic ion-pairing agent compared to
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the sulfate, cLogD7.4 −5.54 (MarvinSketch software (Chem-
Axon). Assuming that salbutamol and 1H2NA are forming an
ion-pair in solution, the overall complex would be more
hydrophobic compared to the sulfate counterion complex, and
thus one may expect the former to show greater aﬃnity to
tissue and a greater propensity to be transported via the
transcellular route.46 Ion-pair transport across the membrane
will not be hindered by charged proteins in the ECM as may be
the case for weak bases such as salbutamol,50 and this could aid
the transport rates across the tissue.
The in vitro studies that investigated the relaxant activity of
salbutamol in the presence of the counterions in isolated guinea
pig tracheal tissue showed only a marginal eﬀect of the
salbutamol:1H2NA complex. The small magnitude of the
response in the isolated tissue model suggested that the
pharmacology of the drug action was not dramatically modiﬁed
as a consequence of ion-pair formation. Therefore, it was
proposed that the ion-pair broke down once taken up into the
tissue. This was supported by the fact that the weaker of the
two ion pairs, the salbutamol sulfate complex, did not show any
eﬀect. It was interesting however that the delayed lag time
shown in the transport studies did not have any consequences
on the pharmacological indices measured both in vitro and in
vivo. In fact the salbutamol-1H2NA ion-pair had a signiﬁcantly
faster onset rate (OT75 only) in addition to a greater degree of
inhibition compared to the base alone, which would not be
predicted when analyzing drug transport across lung trachea. It
was also surprising that the faster onset of pharmacological
action was coupled with a signiﬁcantly faster recovery rate, not
observed with salbutamol sulfate. It was expected that the
1H2NA counterion would provide a slower recovery rate due
to an increase in the hydrophobicity of the complex, but
perhaps if the ion-pair complex was dissociating in the tissue,
this resulted in a complex relationship between the transport
and pharmacological activity.
5. CONCLUSIONS
The results from this study provide evidence that the
counterions included in pharmaceutical salts are important in
determining the biological behavior of the parent drug molecule
when delivered by the inhaled route. These results need
conﬁrmation using pharmaceutical salts in the solid state in
humans, but if these results are replicated in such studies it
would have signiﬁcant implications for the choice of inhaled
drug counterions. It is recommended, based on the data
generated to date, that when counterions are switched in
generic products, careful characterization of the pharmaceutical
alternative’s properties must be undertaken prior to medicine
approval.
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